Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immutep.
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: Percheron ‘closes the book’ on failed childhood rare disease program
Health & Biotech
Health Check: Clinical trials don’t sleigh down for the silly season
Experts
Hot Money Monday: 10 ASX stocks with ‘Strong Buy’ recommendations from brokers
News
Closing Bell: Tech leads and goldies hit hard; Variscan jumps 50pc as Spanish zinc drilling begins
News
ASX Lunch Wrap: Xero lifts ASX higher; Selfwealth skyrockets after attracting another suitor
Health & Biotech
Health Check: Experts deliver their verdict on the Healius imaging deal and it’s ‘yeah nah’
Health & Biotech
Alive and Kicking: Respiri promises breath of life to bottom line after inking US distribution deal
News
Market Highlights: ASX to test new record in a high-stakes week; and 5 small caps to watch
News
ASX Rebalance: Copper in, lithium out as hot biotechs climb ranks
Health & Biotech
Bio Curious: How Dimerix negotiates the ‘valleys of death’ on the winding road to drug approval
Health & Biotech
ASX Health Stocks: Inoviq’s tech boosts early detection of Parkinson’s disease
News
Market Highlights: Wall Street rallies hard after inflation data; Starbucks steals Chipotle’s CEO
Health & Biotech
ASX Health Stocks: Immutep gets positive FDA feedback for lung cancer therapy
News
Market Highlights: CrowdStrike plunges 11pc after global outage, as Biden pulls out of race
Health & Biotech
ASX Health Stocks: Immutep gets crucial therapy trial clearance; Alcidion wins $4m deal
News
Top 10 at 11: A positive drug trial and investor webinars are making news today
Health & Biotech
